Join
Live feed
·
PRReleasevia Quantisnow
Travere Therapeutics Inc. logo

Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

ByQuantisnow·Wall Street's wire, on your screen.
TVTX· Travere Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.